Table 1. Baseline clinical characteristics and laboratory results.
| Risk factors | Total (n = 40,164) | Statin (-) (n = 17,798) | Statin (+) (n = 22,366) |
|---|---|---|---|
| Age (years) | 55.1±9.0 | 52.2±9.4 | 57.4±8.0 |
| Male gender, n (%) | 18,882 (47.0) | 10,653 (59.9) | 8,229 (36.8) |
| Follow-up duration (years) | 7.7±3.2 | 10.2±1.7 | 5.6±2.6 |
| BMI (kg/m2) | 24.5±2.8 | 24.4±2.8 | 24.6±2.8 |
| SBP (mmHg) | 128.6±17.4 | 127.4±17.6 | 129.5±17.1 |
| DBP (mmHg) | 80.5±11.3 | 80.4±11.6 | 80.5±11.0 |
| Total Cholesterol (mg/dL) | 264.8±25.9 | 258.7±23.4 | 269.7±26.8 |
| FSG (mg/dL) | 94.0±12.5 | 92.8±13.1 | 95.0±11.9 |
| Smoking, n (%) | 7,735 (19.3) | 4,916 (27.6) | 2,819 (12.6) |
| Alcohol use, n (%) | 15,822 (39.4) | 8,432 (47.4) | 7,390 (33.0) |
| Exercise, n (%) | 21,148 (52.7) | 7,694 (43.2) | 13,454 (60.2) |
| FHx of type 2 DM, n (%) | 5,504 (13.7) | 2,541 (14.3) | 2,963 (13.3) |
| Duration of statin (years) | - | - | 4.4±2.9 |
| Drug history, n (%) | 6,057 (15.1) | 819 (4.6) | 5,238 (23.4) |
| Use of beta-blocker | 2,181 (5.4) | 359 (2.0) | 1822 (8.2) |
| Use of thiazide | 3,876 (9.7) | 460 (2.6) | 3,416 (15.3) |
BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; FHx, family history; FSG, fasting serum glucose; SBP, systolic blood pressure